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T cells are critical components of adaptive immunity. As such, their activation is regulated
by the T cell receptor (TCR) that constantly scan peptides associated with major
histocompatibility complexes (MHC). TCR engagement initiates a series of molecular
events leading to cytokine secretion, proliferation, and differentiation of T cells. As
a second coincident event, activation of co-stimulatory molecules, such as CD28,
synergize with the TCR in order to prolong and/or amplify intracellular signals. With
the recent advances in immunotherapies targeting T cells, co-inhibitory receptors are
of growing interest for immunologists due to their potential modulatory properties on
T cell functions. However, special attention should be dedicated to avoid unwanted
clinical outcomes (1). In particular, Manichean categorization of receptors based on
incomplete functional knowledge can lead to an over-simplistic view of complex cellular
regulations. Thus, analysis of the functions that characterize these receptors in diverse
physiological contexts remains essential for their rational use in therapeutic protocols.
Here we focus on CD5, a transmembrane receptor that regulates T cell functions and
development but remains poorly characterized at the molecular level. We will review its
roles in physiological conditions and suggest potential molecular effectors that could
account for CD5-dependent regulation of TCR signaling.
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REGULATION OF T CELL DEVELOPMENT AND FUNCTION BY
CD5
Seminal studies have identified CD5 as an activation marker of T cells (2, 3). Thus, expression of
CD5 increases according to the magnitude of the signal delivered by the TCR. Consequently, CD5
expression reflects the heterogeneity of the signal strength associated with each individual TCR
within a polyclonal T cell population. This observation has been also documented with various
TCR transgenic mice, for which CD5 expression levels correlated with the affinity of the TCR with
its known agonist peptide (4, 5). The study of CD5 deficient mice allowed to position CD5 not
only as an activation marker but also as an active player of the TCR signaling pathway (6). Indeed,
absence of CD5 enhanced signaling and activation of double positive (DP) thymocytes induced
by TCR stimulation. Moreover, CD5 deficient DP thymocytes from TCR transgenic mice have a
shifted windows of selection toward a lower threshold, resulting in an enhanced positive or negative
selection with TCRs of low or high avidities, respectively (7, 8). These results established CD5 as a
negative regulator of the TCR signaling pathway in immature thymocytes.
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In contrast to its role in the thymus, the functions of
CD5 in the periphery remain unclear. On the one hand CD5
deficient peripheral T cells showed better proliferative responses
following TCR stimulation than their wild-type counterparts
(8), suggesting that CD5 also acts as a negative regulator
of TCR signaling in mature T cells. On the other hand,
analysis of polyclonal and TCR transgenic T cells showed that
effector functions of mature T cells positively correlate with
CD5 expression (4, 5, 9). As a result, it has been proposed
that the abundance of CD5 can predict TCR avidities with
self and foreign peptides (4). Also, other reports suggested
that CD5hi cells acquired intrinsic properties during thymic
selection against self-peptides that could be maintained in
periphery leading to improved reactivity against foreign antigens
(5, 9).
These complex results illustrate the difficulty of assessing the
impact of altered thymic selection on T cell reactivity in the
periphery. Indeed, comparing results obtained in the periphery
and in the thymus raises several issues. The first issue is that
phenotypic differences observed in peripheral T cells could
result from perturbed thymocyte education. Hence, in the case
of CD5 deficient mice, the increased proliferation observed in
periphery could be due to an alteration of the TCR repertoire
selected during thymic development. Also, changes in selection
pressure could modify the abundance of other regulators of the
TCR signaling pathway. For example, it has been shown that
the abundance of CD6 (a transmembrane receptor structurally
related to CD5) was higher in peripheral T cells deficient for
CD5 (10).The second issue is related to the difficulty of tracking
the same cell during the processes of thymic selection and
egression in vivo. Thus, although CD5 expression correlates with
the magnitude of the TCR signal during DP selection and of
tonic TCR signals in periphery, it does not necessarily indicate
that a CD5hi cell in the thymus remains CD5hi in the periphery.
Indeed, it is possible that selecting self-peptides are absent in the
periphery or do not induce a similar TCR reactivity as they did
during thymocyte selection. The above issues make it difficult to
distinguish between direct CD5 signaling effects in peripheral T
cells from indirect consequences of perturbed thymic selection.
Conditional deletion of CD5 in peripheral T cells would greatly
help elucidate the role of CD5 in periphery independently of its
effect on thymic selection.
STRUCTURAL BASIS FOR THE NEGATIVE
REGULATION EXERTED BY CD5
From a structural point of view, CD5 is a type-I transmembrane
glycoprotein with an extracellular region composed of three
scavenger receptor cysteine-rich (SRCR) domains. Several CD5
ligands have been reported such as CD72, the IgV(H) frame-
work region and several polypeptides (gp40-80, gp150) whose
identity remains undetermined (3, 11, 12). CD5 can also
establish low stoichiometric homophilic interactions in cis
or in trans (13). Whether these molecules bind to CD5
and modulate its activity in physiological settings remains
a matter of debate. Even so, it has been reported that
cross-linking of antibodies targeting the extracellular domain
of CD5 induces signaling in the Jurkat cell line (14).
In the absence of binding of CD5 with potential ligands,
TCR stimulation triggers CD5 phosphorylation on tyrosine
residues (15) and its translocation into the immunological
synapse (16), thereby indicating a direct regulation of CD5
by TCR signals. Both types of stimulation suggest that CD5-
mediated signaling inhibition could be potentiated by spatial
confinement in areas where phosphatases are excluded and
kinases enriched.
On its cytoplasmic tail, CD5 contains four tyrosine residues
at position 402, 453, 464, and 486 in human (historically
Y378, Y429, Y441, and Y463 if the signal peptide sequence is
not included) exposed to potential phosphorylation regulations.
Although the tyrosine Y402 was initially associated with
the CD5 inhibitory signal through its association with the
SH2 domain containing-tyrosine phosphatase 1 (SHP-1) (17),
cumulative data from mass spectrometry analysis failed to detect
phosphorylation at this position even though the corresponding
peptide bearing this tyrosine residue is frequently observed
(source: phosphosite.org and peptideatlas.org). In contrast, the
three distal tyrosine residues (Y453, Y464, and Y486) have been
frequently observed in their phosphorylated form. Moreover,
studies using either phosphopeptides coding for CD5 tyrosine
motifs or B cells transfected with a chimeric molecule composed
of the extracellular and the transmembrane domains of FcgRIIB
with the cytoplasmic domain of CD5 did not detect SHP-
1 interaction (18, 19). Consistently, analysis of truncated
mutants of CD5 demonstrated that the cytoplasmic tail of CD5
comprising these three distal tyrosines residues could account for
global CD5 phosphorylation following pervanadate stimulation
and was required for CD5 signaling activity (7). These three
distal tyrosine residues are subjected to Src kinases regulation
and have been proposed as docking sites for several effectors
such as the RasGAP or the phosphatidylinositol 3-kinase (PI3K)
(18, 20). In addition to the tyrosine dependent interactions, it
has been shown that the two carboxy-terminal serine residues
of CD5 allow constitutive binding with the casein kinase 2
(CK2) (21). Transgenic mouse models for which the CD5 serine
motif has been deleted display abnormal T cell development and
perturbed differentiation of mature T cells (22, 23). Moreover,
T cells from these mice exhibit reduced survival capacity and
hypoproliferate in response to TCR stimulation. These studies
illustrate that CD5 signal transduction relies on both tyrosine and
serine motifs.
More recently, our group demonstrated that CD5 could
associate with CBL, CBLB, and GRB2 in mature CD4+
T cells upon TCR stimulation (24, 25). To do so, we
developed mouse models suitable for proteomics analysis
in primary T lymphocytes. These mice are genetically
engineered to express proteins bearing an OST tag at their
N terminal, thereby serving as “baits” allowing affinity
purification (AP) of protein complexes. AP samples are
subjected to tandem mass spectrometry (MS-MS) and
specific binding partners are identified by comparing protein
intensities in samples from cells bearing the endogenous
or the OST-tagged proteins. Using this approach, the set
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of specific binding partners for a protein of interest, its
“interactome,” can be quantified in a comprehensive manner.
We discuss in the following how the molecular mechanisms
of CD5 signaling might be revisited in light of these recent
results.
COOPERATIVITY BETWEEN CD5 AND THE
UBIQUITIN LIGASES CBL AND CBLB IN
MATURE T CELLS
CBL molecules (CBL and CBLB) are E3-ubiquitin ligases
involved in the negative regulation of the TCR signaling pathway
via different complementary mechanisms (26). CBL has been
shown to control ubiquitination and degradation of the CD3
chains and activities of the proximal tyrosine kinases LCK and
ZAP70 (27–29) whereas CBLB negatively regulates the CD28
co-stimulatory pathway by dampening the PI3K activity (30–32).
CBL and CBLB both target specific substrates for
ubiquitination. Globally, CBLB proximal molecular environment
contains more ubiquitinated species than CBL, suggesting a
predominant role of CBLB over CBL for this post-translational
regulation in mature T cell (24). This observation correlated
with the severe phenotype of the Cbl-b−/− T cells exhibiting
an increased capacity to proliferate and secrete cytokines when
activated (30, 31).
Because CBL and CBLB interact together (24, 33) (Figure 1),
it is possible that the scaffolding property of each ubiquitin ligase
allows trans-ubiquitination of contiguous proteins not subjected
to cis-ubiquitination. For example, although PI3K subunits are
specifically associated with CBL in peripheral T cells, their
ubiquitination is mainly regulated by CBLB (24, 32).
In peripheral T cells, both CBL and CBLB associated with CD5
upon TCR stimulation (24). This suggests that CD5 could play a
scaffolding role, facilitating the CBL-CBLB relocalization to the
plasma membrane in proximity of the tyrosine kinases required
for their activities. This cooperativity between CBL, CBLB, and
CD5 could also be important for enhancing ubiquitination within
supra molecular complexes assembled upon TCR stimulation. In
line with this model, mature T cell from CD5 deficient mouse
showed reduced CBL-dependent ubiquitination in activated T
cells (24). More specifically, ubiquitination of PI3K subunits
following TCR stimulation was reduced in the absence of CD5
suggesting that CD5 could facilitate trans-ubiquitination.
In the CBLB deficient T cells, association of CD5 with CBL
was preserved. Interestingly, the absence of CBLB enhanced the
interaction between CD5 and CBL and increased global protein
ubiquitination within the complex formed around CBL (24).
These results suggest that CBL molecules compete for binding
to shared docking sites on CD5 and in the ubiquitination of
shared substrates. Also, they indicate that despite a molecular
reorganization in the absence of CBLB, CBL is unable to fully
compensate for CBLB deficiency in mature T cells. Hence, in
peripheral T cells, CD5 could negatively control TCR signaling
by coordinating ubiquitination through its interaction with CBL
and CBLB.
INTERACTIONS BETWEEN CD5 AND CBL
IN THYMOCYTES
The situation described above is modified in thymocytes where
abundances of CBL molecules differ from that in mature T cells.
While CBL and CBLB have similar abundances in peripheral
T cells, protein expression of CBLB is much lower than CBL
in thymocytes (24). In agreement with observations reported in
CBLB deficient mature T cells, analysis of the CBL interactome in
thymocytes revealed that the association between CD5 and CBL
is maintained despite the low abundance of CBLB (Figure 1).
These results suggest the existence of a functional relationship
between CBL and CD5 in thymocytes. The comparison of the
phenotypes between the CBL and CD5 deficient mice partially
supports this hypothesis. Indeed, both CBL and CD5 deficient
DP thymocytes show enhanced intracellular signaling which,
onto a low avidity TCR transgenic background, lead to increased
positive selection (35, 36). However, in contrast to CD5−/− mice,
DP thymocytes of CBL−/− mice have elevated TCR levels due to
reduced TCR degradation and increased TCR recycling (37, 38).
Thus, increased TCR reactivity in CBL−/− DP thymocytes could
essentially reflects the increased abundance of the TCR at the
plasmamembrane. This phenotype might mask another function
of CBL. Indeed, considering that the interaction between CBL
and CD5 depends on TCR stimulation, the increased TCR
responses observed in CD5 deficient mouse could reflect a
specific role of CBL strictly dependent on TCR engagement.
Hence, two mechanisms of TCR signaling regulation involving
CBL could coexist (Figure 2A). One where CBL, independently
of CD5, regulates the constitutive TCR pool at the surface of DP
thymocytes and another one, triggered by the TCR stimulation,
relocating a fraction of CBL molecules to the synapse via
CD5 and promoting its inhibitory activity (ubiquitination) in
this particular cellular localization. In this molecular context,
specific effectors of the proximal TCR signaling pathway could
be negatively controlled by CBL.
Hence, both in thymocytes and in mature T cells, CBL
molecules are possible molecular mediators of CD5 inhibition of
TCR signaling (Figure 2B).
CONTRIBUTIONS OF UBASH3A/B
MOLECULES TO CD5 INHIBITION
Other molecules than CD5 associated with both CBL and CBLB
in TCR stimulated mature T cells (24). Among them, the
Ubiquitin-associated and SH3 domain-containing protein A and
B (UBASH3A, UBASH3B also known as STS-2 and STS-1) have
been associated with negative regulation of the TCR signaling
pathway (39) and might therefore participate in CD5 inhibition.
Association of CBL with UBASH3A was detected in
unstimulated thymocytes and mature T cells and remained
unchanged upon TCR stimulation (Figure 1). In contrast,
UBASH3B was associated with CBL only upon TCR stimulation
and this recruitment correlated with that of CBLB. This suggests
preferential associations of CBL with UBASH3A and CBLB with
UBASH3B. In support of this statement, the expression pattern of
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FIGURE 1 | Association of selected proteins with CBL in thymocytes and mature T cells. Mature CD4+ T cells and thymocytes from wild-type (WT) and gene-targeted
mice expressing One-STrEP-tag at the carboxyl-terminus of endogenous CBL (CBL-OST) were left unstimulated (unstim.) or stimulated for 30 s (stim.) with anti-CD3
plus anti-CD4 antibodies and subsequently lysed. Protein lysates were subjected to OST affinity purification coupled to mass spectrometry analysis (AP-MS) (24, 34).
For each sample, protein intensities were log transformed and normalized by the sample median intensity. Intensities were then averaged across technical replicates
and missing values imputed by values simulating noise around the detection limit. After missing values imputation, log-transformed intensities from WT and CBL-OST
cells were compared using a two-sided Welch t-test (symbols used according to the t-test P-value: N.S., P > 0.05; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). Intensities
were divided by the minimum intensity across all intensities represented to ensure that all log-transformed values were positive. Data used for mature CD4+ T cells are
from Voisinne et al. (24) (NA, non-applicable).
UBASH3A andUBASH3B proteins in alpha/beta T cells is similar
to that of CBL and CBLB, respectively (39) (www.immgen.org).
Hence, UBASH3A is highly expressed in DP thymocytes whereas
expression of UBASH3B starts in single positive (SP) thymocytes.
Both UBASH3 molecules exert phosphatase activities and
bind ubiquitinated proteins though their UBA domains (40, 41).
When both molecules are inactivated, mature T cells showed
an enhanced capacity to proliferate and secrete cytokines,
a phenotype reminiscent of those observed with CD5 and
CBLB deficient mice (39). In addition, in dually UBASH3
deficient mouse, TCR stimulation triggers increased tyrosine
phosphorylation and ubiquitination of signaling effectors
(39). The simultaneous increase of these post-translational
modifications could be due to the fact that the activation-
deactivation sequence of specific effectors is stopped at a stage
where they have been phosphorylated by tyrosine kinases,
ubiquitinated by CBL molecules but subsequently improperly
dephosphorylated or targeted for degradation as they should
when UBASH molecules bind to ubiquitin. As confirmed by
recent studies, one of the first targets of this regulation is ZAP-70
(42, 43). In this context, it is possible that CD5 allows molecular
cooperativity between CBL and UBASH3 molecules to terminate
TCR induced signaling by dampening the activity of ZAP-70
kinase and by contributing to its degradation (Figure 2B).
CD5-MEDIATED REGULATION OF CSK
Another potential mediator of the CD5 inhibition that was also
detected with both CBL and CBLB after TCR engagement is
the tyrosine kinase CSK. The recruitment of CD5 and CSK to
both CBL molecules was correlated indicating a possible physical
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FIGURE 2 | (A) A model of signaling in double positive (DP) thymocytes from wild-type, CBL−/− and CD5−/− mice. Prior selection (left), constitutive TCR
internalization, recycling and degradation are regulated by CBL. CD5 is not involved in these processes but CD5 protein level is transcriptionally controlled by weak
constitutive TCR signaling (green arrow). In the absence of CBL, surface TCR concentration increases which enhances transcription of CD5. Surface TCR
concentration is unaffected in CD5 deficient cells and remains controlled by CBL. During selection (right), CBL associates with CD5 within the immunological synapse
(IS) to negatively control TCR signaling. In the absence of CBL, TCRs accumulate at the cell surface leading to increased TCR signaling. The inhibition of TCR signaling
by CD5 is impaired in the absence of CBL. In CD5 deficient cells, recruitment of CBL to the immunological synapse (IS) is impaired which leads to enhanced TCR
signaling. (cTEC: Cortical thymic epithelial cell) (B) A model of CD5 signaling in thymocytes and mature T cells. Upon TCR engagement, LCK phosphorylates the CD3
chains and CD5 (blue arrows). Phosphorylation of CD5 allows interactions of inhibitory molecules such as CBL and UBASH3 proteins triggering post-translation
modifications (ubiquitination, dephosphorylation) of positive effectors (ZAP70, PI3K) involved in the proximal TCR signaling pathway. The global negative signal
mediated by CD5 is symbolized by the inhibitory red line. In thymocytes, CBLB and UBASH3B expressions are undetectable, CD5 associated only with CBL and
UBASH3A. The PI3K interacts with CBL in thymocytes and in peripheral T cells. PI3K regulation by ubiquitination is essentially mediated by CBLB. (C) An alternative
model of CD5 signaling involving CSK. In quiescent T cells CSK interacts with PAG to negatively control LCK (1). Upon TCR engagement LCK phosphorylates CD5
(2). CSK molecules associated with phosphorylated CD5 localized into the IS. CD5-associated CSK phosphorylates the inhibitory tyrosine residue of LCK thereby
reducing the magnitude of TCR signaling (3). Panel (A) was modified from Servier Medical Art, licensed under a Creative Common Attribution 3.0 Generic License.
http://smart.servier.com/.
association between them. This association was confirmed by co-
immunoprecipation of CSK with CD5 upon TCR stimulation
(24). CSK has been shown to control the activity of Src kinases by
phosphorylating their C-terminal tyrosine residue (44). In turn,
CSK activity depends on its association with the transmembrane
adaptor PAG (45, 46). In this context, CD5 ligation was shown
to induce the phosphorylation of the Src kinase Fyn at its C-
terminal inhibitory residue and attenuate its activity (14). To
explain this observation, it has been proposed that CD5 could
interfere with the disassembly of the CSK-PAG complexes during
T cell activation. However, in contrast to CSK and CD5, PAG
was not identified as a binding partner of either CBL or CBLB in
TCR stimulated mature T cells. This suggest that different pools
of CSK are present in T cells, within different protein complexes.
Moreover, a recent study has demonstrated that PAG-regulated
TCR signaling is essentially active in effector T cells (47). Thus,
it is conceivable that the facilitation of CSK recruitment to
the synapse could operate through alternative transmembrane
adaptors, and possibly directly with CD5, depending of the
activation state of T cells. An attractive model could be that
CD5 binds to CSK through its SH2 domain. In this setting, the
interaction between CD5 and CSK, induced by TCR stimulation,
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could participate in a negative feedback loop by reducing the
activity of Src kinase recruited to the synapse (Figure 2C).
CD5 AND IMMUNOTHERAPY
Accumulated knowledge on immunomodulatory properties of
CD5 positions this receptor as a putative checkpoint inhibitor,
potentially useful in the context of immunotherapies. In this
context, one way to harness the inhibitory functions of CD5
would be the development of anti-CD5 monoclonal antibodies
(mAb) having diverse functional properties. Thus, mAb with
the ability to sequester the receptor away from the T cell
synapse could be useful to reduce CD5 inhibitory signaling and
increase T cell responses against tumors. Alternatively, anti-CD5
mAbs enhancing the inhibitory role of the receptor could help
improve autoimmune diseases by reducing effector functions of
autoreactive T cells.
Prior the emergence of antibody-based cancer treatments,
results of clinical trials using anti-CD5 mAb have established
moderated benefit in patients with chronic lymphocyte leukemia
or cutaneous T-cell lymphomas (48, 49). With the recent
advances in immunotherapies, experimental protocols have
evolved and critical factors have been identified to improve
treatment efficacies. For example, manipulation of antibody
structure to avoid rapid clearance and immune response against
the therapeutic mAb is one of the issue that could be investigated
with CD5. Also, evaluation of biological effects provided by
combination with other antibodies in a broader spectrum of
malignancies could reveal CD5 as a potent target to control
cancer.
However, immunotherapy strategies targeting CD5 should be
the object of cautious attention. Indeed, as CD5 is expressed in
all T cell subsets and on B-1a B cells, in vivo administration of
CD5 specific antibodies will result in the sum of individual cell
type responses. For example, it has been shown that generation
of induced Treg (iTreg) cells is altered among CD5 low or
CD5 deficient T cell populations (50). It is therefore likely
that inhibition of CD5 would simultaneously reduce iTreg cell
number and activate effector functions on conventional T cells,
thereby increasing T cell reactivity against self and potentiating
auto-immune disorders. In addition and as proposed by studies
using a mouse expressing a serine-truncated CD5 form, signaling
of the receptor can also affect T cell differentiation toward specific
Th subsets (51). Therefore, all these parameters must be taken
into consideration in order to avoid the onset of undesirable
reactions resulting from complex global effects.
CONCLUDING REMARKS
Overall, it appears that distinct molecular mechanisms remain
possible to explain the negative regulation of TCR signaling
exerted by CD5 in thymocytes, naïve and effector T cells. As
illustrated by the different signaling models presented here,
CD5 could act as a scaffold coordinating the action of CBL,
UBASH3 and CSK molecules within the immunological synapse.
In conclusion, CD5 and the identified effectors involved in the
same signaling pathway offer great potential for the development
of new drugs. However, complexity of themolecular relationships
and difficulties to predict perturbations of the system must
be taken into account prior to the design of new therapeutic
strategies.
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